Back to Search
Start Over
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.
- Source :
-
American journal of clinical pathology [Am J Clin Pathol] 2014 Dec; Vol. 142 (6), pp. 795-802. - Publication Year :
- 2014
-
Abstract
- Objectives: We retrospectively tested the prognostic and diagnostic significance of CD271+ mesenchymal stromal cell (MSC) density in cytopenic patients who underwent bone marrow biopsy to evaluate for myelodysplastic syndromes (MDS).<br />Methods: CD271+ MSC density was quantitated by automated image analysis of tissue microarray cores in 125 cytopenic patients: 40 lower grade MDS (<5% marrow blasts), 24 higher grade MDS, and 61 benign.<br />Results: CD271+ MSC density was increased in higher grade MDS compared with benign (P = .006) and lower grade MDS (P = .02). CD271+ MSC density was predictive of survival among patients with MDS independent of Revised International Prognostic Scoring System (IPSS-R), history of transfusion, therapy-related MDS, and fibrosis (hazard ratio, 3.4; P < .001). Among low or intermediate IPSS-R patients, median survival was significantly shorter in the high CD271+ MSC density group (47 vs 18 months, P < .02).<br />Conclusions: High CD271+ MSC density is characteristic of higher grade MDS and is associated with poor risk independent of known prognostic factors.<br /> (Copyright© by the American Society for Clinical Pathology.)
Details
- Language :
- English
- ISSN :
- 1943-7722
- Volume :
- 142
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- American journal of clinical pathology
- Publication Type :
- Academic Journal
- Accession number :
- 25389333
- Full Text :
- https://doi.org/10.1309/AJCP71OPHKOTLSUG